SCHEMBL899736

SCHEMBL899736

Oc1ccc(C2CC3CC2CC3c2ccccc2)cc1C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NUDT1 P36639 1/20 0.43
BACE1 P56817 1/20 0.43
HSP90AA1 P07900 1/20 0.43
ACMSD Q8TDX5 2/20 0.41
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
HDAC4 P56524 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
KMO O15229 1/20 0.36
THRB P10828 1/20 0.36
IGF1R P08069 1/20 0.35
ALOX15 P16050 1/20 0.35
KDM1A O60341 3/20 0.35
MAOA P21397 3/20 0.35
MAOB P27338 3/20 0.35
HPGD P15428 1/20 0.34
DHODH Q02127 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9008321 0.80 NUDT1 (0.53) MEN1KMT2ANUDT1BACE1HSP90AA1
SCHEMBL899421 0.79 MEN1 (0.66) MEN1KMT2ANUDT1BACE1HSP90AA1
SCHEMBL19665789 0.77 ACMSD (0.59) NUDT1BACE1HSP90AA1ACMSDHDAC4
SCHEMBL918287 0.77 ACMSD (0.59) NUDT1BACE1HSP90AA1ACMSDHDAC4
SCHEMBL899891 0.76 NUDT1 (0.38) MEN1KMT2ANUDT1BACE1HSP90AA1
SCHEMBL899897 0.76 NUDT1 (0.38) MEN1KMT2ANUDT1BACE1HSP90AA1
SCHEMBL899717 0.75 NUDT1 (0.34) MEN1KMT2ANUDT1BACE1HSP90AA1
SCHEMBL899712 0.75 MEN1 (0.38) MEN1KMT2ANUDT1BACE1HSP90AA1
SCHEMBL6940007 0.75 ACMSD (0.58) MEN1KMT2ANUDT1BACE1HSP90AA1
SCHEMBL8509094 0.75 MEN1 (0.44) MEN1KMT2APOLBGAAKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9261781-B2 Preparation of norbornane-based PAC ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2016-02-16 US claimed
US-20130323640-A1 Preparation of Norbornane-based PAC Ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2013-12-05 US claimed
US-9261781-B2 Preparation of norbornane-based PAC ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2016-02-16 US disclosed
US-20130323640-A1 Preparation of Norbornane-based PAC Ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2013-12-05 US disclosed
US-8530133-B2 Preparation of norbornane-based PAC ballasts PROMERUS, LLC (US) 2013-09-10 US disclosed
EP-2622410-A1 NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC Promerus, LLC (US) 2013-08-07 EP disclosed
US-20120135352-A1 Preparation of Norbornane-based PAC Ballasts PROMERUS LLC (US) 2012-05-31 US disclosed
WO-2012044719-A1 NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC PROMERUS LLC (US) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135352-A1 Preparation of Norbornane-based PAC Ballasts NBAS, PHB2, BDNF MEN1 2147/4885KMT2A 701/4885NUDT1 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.